Biotechnology companies apply biological science to develop products, services and technologies that address challenges in healthcare, agriculture, industry and environmental sustainability.
This category includes companies working on:
Browse 360 UK biotechnology companies below.
Engineered patient cells for sustained therapeutic antibody production
Semper-B Therapeutics is a biotechnology company developing a cell-engineering platform intended to enable patients’ own cells to produce therapeutic antibodies over prolonged periods. The approach aims to achieve durable, precise modulation of immune activity by using engineered cells as a continuing source of…
Endometrial biology platform for implantation failure and miscarriage
Sita Bio is a London-based biotechnology company engineering functional, vascularised thick living tissue. Combining tissue engineering, vascular biology, perfusion hardware and automated experimentation, it builds living systems that survive, organise and adapt. Its first application is a first-trimester uterine…
Small molecule inhibitors targeting APOBEC enzymes in cancer
Apobec Discovery is a preclinical-stage biotechnology company developing first-in-class small molecule inhibitors of APOBEC3A and APOBEC3B, cytidine deaminase enzymes that drive tumour mutagenesis, evolution, and resistance to treatment. By blocking APOBEC activity, the company aims to limit the mutational capacity of…
Engineered immune cells as living delivery vehicles for genetic medicines
Dart Biosciences is a biotechnology company developing a platform that uses engineered immune cells as living delivery vehicles for genetic medicines. By leveraging immune cells' natural ability to localise to disease-relevant tissues, the platform aims to achieve more spatially precise genetic payload transfer with…
Clinical-stage therapeutics for advanced liver disease
Yaqrit is a clinical-stage biotechnology company developing treatments for patients with advanced liver disease, including cirrhosis and acute-on-chronic liver failure. Its pipeline includes an oral ammonia scavenger for hepatic encephalopathy, an extracorporeal liver support device, and a microbiome-based…
Xeno nucleic acid binders for targeted drug delivery
Xterna is a biotechnology company developing cell-specific molecular binders composed of xeno nucleic acids (XNAs), chemically modified nucleic acids distinct from naturally occurring DNA and RNA. XNA-based binders are engineered to target cell types that evade conventional antibody-based approaches, enabling drug…
Engineered cell-derived vesicles for targeted RNA and drug delivery
AAB Therapeutics develops programmable nanovesicles from engineered human cell membranes for targeted intracellular drug delivery. The vesicles are designed to carry RNA, small molecules or biologics, using surface targeting molecules and fusogenic proteins to release their cargo into cells. The preclinical company…
Enzyme-enabled precision molecular editing for therapeutic discovery
X-Genix is a biotechnology company developing enzyme-enabled methods for selective molecular modification in drug discovery. Its platform integrates engineered biological catalysts, synthetic chemistry and machine learning to modify small molecules and complex biomolecules at defined sites. This provides access to…
Genetically diverse iPSC models and high-throughput drug screening
Cytochroma is an Edinburgh biotechnology company producing genetically diverse human induced pluripotent stem cell-derived models for drug discovery and safety research. Its donor-matched panels include hepatocytes, cardiomyocytes and supporting cell types, enabling assessment of drug responses across different…
Bio-inspired adhesion peptides for medical and industrial use
Zentraxa is a biomaterials company engineering bio-inspired adhesion peptides using a proprietary synthetic peptide manufacturing platform. Inspired by marine mollusc chemistry, the platform designs and produces novel peptides with exceptional adhesion properties in wet and submerged environments. Medical applications…
Engineered bacteria to remodel the tumour microenvironment
Neobe Therapeutics is a UK synthetic biology company developing programmable live biotherapeutics that colonise solid tumours and disrupt the local microenvironment to enable immune cell infiltration. The platform engineers tumour-colonising bacteria to break down stromal barriers that exclude immune cells, aiming to…
Microgravity-based CDMO platform for crystallisation of biologic drugs
BioOrbit is a biotech developing a proprietary hardware platform for the crystallisation of protein-based biologic drugs in low Earth orbit. The company exploits the absence of gravity-driven convection in microgravity to produce larger, more uniform protein crystals than ground-based methods allow, enabling…
AI-powered portable diagnostics platform for field-based disease testing
Vidiia is a diagnostics company developing AI-powered, portable molecular testing devices for point-of-care and field-based disease detection. Its platform combines RT-LAMP assay chemistry with smartphone-connected artificial intelligence to interpret results, and has received UK regulatory approval for medical use.…
Plasma amino acid biomarkers for multi-cancer risk assessment
Proteotype Diagnostics develops blood tests to support earlier assessment of possible cancer. Its Enlighten test measures patterns of circulating amino acids in plasma and applies machine learning to estimate the likelihood of malignancy across several solid tumour types. It is designed to inform further clinical…
Enzymatic wound debridement therapy derived from maggot biology
SolasCure is a biotechnology company developing a recombinant enzyme-based hydrogel for the treatment of chronic wounds. The lead product contains a protease cloned from medical maggots that degrades non-viable wound tissue including fibrin, elastin, and collagen to prepare the wound bed for healing. The product is in…
Antibody inhibitors of metzincin proteases for eye disease and cancer
Vasgen develops antibody therapeutics for eye disease and cancer, focusing on enzymes known as metzincin proteases. Its discovery platform uses monoclonal antibodies to inhibit these enzymes selectively, offering a different approach to targets that have proved challenging for conventional small-molecule medicines.…
Preclinical RNA medicines for chronic liver disease and fibrosis
Afortiori Bio is a preclinical biotechnology company developing RNA medicines for chronic liver disease, particularly liver fibrosis. Its lead programme uses Target Site Blocker RNA technology to selectively modulate gene expression in liver cells. The approach is intended to address processes contributing to fibrotic…
AI-driven intron technology to enhance transgene expression
ExpressionEdits is a biotechnology company developing computational tools to improve protein expression from artificial gene constructs. Its Genetic Syntax Engine uses machine learning and biological data to predict optimal intron insertion patterns within transgenes, increasing protein production levels in mammalian…
AI-driven neural data platform for bioelectronic medicine
BIOS Health is a neural engineering company developing an AI-powered platform that reads and interprets peripheral nervous system signals in real time. Its technology links nerve activity to physiological conditions through the discovery of neural biomarkers, supporting the development of personalised neuromodulation…
AI-powered infrared diagnostic test for breast cancer recurrence risk
Digistain is a biotechnology company developing MHRA-cleared diagnostic technology for predicting breast cancer recurrence risk. The platform uses infrared spectrometry to generate spectroscopic signatures from tumour biopsy tissue, with AI analysis producing a personalised prognostic score indicating the likelihood…